Hugel FY 2025 Annual ReportBeta
Hugel annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 20, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).
Hugel FY 2025 Annual Report Analysis
Business Overview
- • Core revenue from Botox toxin (54.22%), HA filler "The Chaeum" (30.63%), cosmetics "Wellage" (13.25%), medical devices (1.27%) in FY2025
- • FDA approval Feb 29, 2024 for botulinum toxin product "Letybo" (50unit, 100unit) in US, first Korean toxin in all 3 major markets (US, EU, China)
Management Discussion & Analysis
- • Revenue KRW 425.1B (+14.0% YoY), Operating Profit KRW 200.9B (+20.8%), Net Income KRW 147.0B (+2.7%) for FY2025
- • Botulinum toxin sales growth driven by domestic market leadership and above-expected shipments in China and U.S.
Risk Factors
- • USD 10% exchange rate change → ±KRW 8.46B pre-tax impact on income, largest FX exposure among currencies
- • Credit risk exposure totaled KRW 629B at FY2025-end, up from KRW 491B at FY2024-end
Hugel FY 2025 Key Financial MetricsDART
Total Assets
KRW 1.08T
▲ +14.6% YoY
Operating Cash Flow
KRW 150.1B
▲ +0.7% YoY
CapEx
KRW 13.4B
▲ +8.4% YoY
Source: KIFRS consolidated financial data from Hugel annual report on DART. All figures in KRW.
Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding